Although anemia is a well-known risk factor for the development of cardiovascular disease in patients with chronic kidney disease, a number of prospective clinical trials have shown that treatment of anemia does not improve cardiovascular outcomes. The primary findings of TREAT, the largest trial to date investigating anemia treatment in patients with chronic kidney disease, have been eagerly awaited.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Regidor, D. L. et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J. Am. Soc. Nephrol. 17, 1181–1191 (2006).
Collins, A. J. et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J. Am. Soc. Nephrol. 12, 2465–2473 (2001).
Locatelli, F. et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol. Dial. Transplant. 19, 121–132 (2004).
Besarab, A. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 339, 584–590 (1998).
Drüeke, T. B. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 355, 2071–2084 (2006).
Singh, A. K. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085–2098 (2006).
Pfeffer, M. A. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. 361, 2019–2032 (2009).
Parfrey, P. S. et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J. Am. Soc. Nephrol. 16, 2180–2189 (2005).
Strippoli, G. F., Navaneethan, S. D. & Craig, J. C. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD003967. doi:10.1002/14651858.CD003967.pub2 (2006).
Szczech, L. A. et al. Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes. Kidney Int. 74, 791–798 (2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares associations with the following companies: Affymax (consultant, grant/research support); Amgen (consultant, honoraria, grant/research support); FibroGen (grant/research support); Hospira (consultant, honoraria, grant/research support); Janssen-Cilag (consultant, honoraria, grant/research support); Roche (consultant, honoraria, grant/research support).
Rights and permissions
About this article
Cite this article
Wiecek, A. To TREAT or not to TREAT—that is the question. Nat Rev Nephrol 6, 254–255 (2010). https://doi.org/10.1038/nrneph.2010.35
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2010.35
